Cytokinetics, Inc. (CYTK)
NGS · Common · CUSIP 23282W605
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for CYTK and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
23282W605 (prev. 23282W100 )
Market Cap
Small Cap · $468 Million
Business: Cytokinetics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics’ research and development activities relating to the biology of muscle function have evolved from a knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics’ current research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle.

Company Contact

CEO
Robert I. Blum
CFO
Ching W. Jaw
Headquarters
280 East Grand Avenue, South San Francisco, CA 94080
Phone
650-624-3000
Fax
650-624-3070
Investor Relations
Diane Weiser · 650-624-3060 · investor@cytokinetics.com
Email Form
Request Form »
SEC EDGAR Filings
View filings »